Konstantinos Makris

Dr. Konstantinos Makris

Clinical Biochemistry Department, KAT General Hospital, Kifissia, 14561, Athens, Greece
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in JACC
Verified
Journal Article
Closed access
MHMichael Haase
Michael Haase
PDPrasad Devarajan
Prasad Devarajan
AHAnja Haase-Fielitz
Anja Haase-Fielitz
RBRinaldo Bellomo
Rinaldo Bellomo
DCDinna N. Cruz
Dinna N. Cruz
PMPeter R. Mertens
Peter R. Mertens

1 May 2016
Verified
Journal Article
Closed access
Konstantinos MakrisKonstantinos Makris
Konstantinos Makris
LSLoukia Spanou
Loukia Spanou

22 April 2020 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
JMJoan Montaner
Joan Montaner
LRLaura Ramiro
Laura Ramiro
ASAlba Simats
Alba Simats
STSteffen Tiedt
Steffen Tiedt
Konstantinos MakrisKonstantinos Makris
Konstantinos Makris
ABAlejandro Bustamante
Alejandro Bustamante

28 March 2025 in Osteoporosis International
Verified
Journal Article
Open access
PDF file
HBHarjit Pal Bhattoa
Harjit Pal Bhattoa
SVSamuel Vasikaran
Samuel Vasikaran
ITIoulia Trifonidi
Ioulia Trifonidi
GKGeorgia Kapoula
Georgia Kapoula
Giovanni LombardiGiovanni Lombardi
Giovanni Lombardi
ECEtienne Cavalier
Etienne Cavalier
Purpose The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis. Methods Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined. Results Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications. Conclusion We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis.

1 January 2009 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
Konstantinos MakrisKonstantinos Makris
Konstantinos Makris
NMNikos Markou
Nikos Markou
EEEffimia Evodia
Effimia Evodia
EDEleni Dimopoulou
Eleni Dimopoulou
IDIoannis Drakopoulos
Ioannis Drakopoulos
AHAlexander Haliassos
Alexander Haliassos
Neutrophil gelatinase-associated lipocalin (NGAL), an iron-transporting protein rapidly accumulating in the kidney tubules and urine after nephrotoxic and ischemic insults, has been put forward as an early, sensitive, non-invasive biomarker for acute kidney injury (AKI). The aim of this study was to evaluate urinary NGAL levels as a predictor of early AKI (first 5 days after injury) in multi-trauma patients. We studied multi-trauma adult patients admitted to the intensive care unit of a trauma hospital. Exclusion criteria were a) known cardiac or chronic kidney disease, and b) initial evaluation after more than 24 h had elapsed from injury. Urinary NGAL was measured using an ELISA technique upon admission and at 24 and 48 h. Presence of AKI was defined by the risk injury failure loss and end-stage kidney classification (RIFLE) criteria. Data are reported as median and interquartile range. A total of 31 patients (25 male, 6 female) were studied. NGAL levels at admission were significantly higher among patients who subsequently developed AKI [155.5 (50.5-205.9) ng/mL vs. 8.0 (5.7-17.7) ng/mL, p=0.0000] and these higher levels persisted over the following 2 days. On the basis of receiver-operating characteristic analysis both NGAL and serum creatinine baseline measurements could predict AKI [area under the curve (95% confidence interval) 0.977 (0.823-0.980) and 0.789 (0.556-0.906), respectively], but the area under the curve for NGAL was significantly larger (p=0.024). A cut-off point >25 ng/mL for NGAL had a sensitivity of 0.91 and specificity of 0.95 in predicting AKI. Urinary NGAL can be used from the 1st day of injury as a reliable predictor of early AKI in multi-trauma patients.

18 April 2018 in Critical Reviews in Clinical Laboratory Sciences
Verified
Journal Article
Closed access
Konstantinos MakrisKonstantinos Makris
Konstantinos Makris
AHAlexander Haliassos
Alexander Haliassos
MCMaria Chondrogianni
Maria Chondrogianni
GTGeorgios Tsivgoulis
Georgios Tsivgoulis
Fast and accurate diagnosis of stroke is crucial for the immediate application of the right therapy to patients. However, rapid diagnosis is still a challenge since an ischemic stroke cannot be identified based only on clinical assessment. CT or MRI imaging is required to rule out hemorrhagic stroke since thrombolytic therapy can lead to increased intracranial bleeding and further aggravation of hemorrhagic stroke. In addition, clinical situations that imitate the signs and symptoms of stroke may also impede the rapid diagnosis and treatment of stroke victims. It is therefore of value to discover non-invasive tests that aim to quickly distinguish stroke from stroke mimics and distinguish ischemic from hemorrhagic stroke. Identifying blood biomarkers of stroke is an active area of research since their potential use is not limited to diagnosis and differentiation, but can be applied to prognosis and patient monitoring – monitoring the effectiveness of applied therapy and/or diagnose possible complications. However, their use has been limited so far not only for reasons related to patients and the disease (heterogeneity of stroke etiology, the complexity of the ischemic cascade, the impact of the blood–brain barrier (BBB) on diffusion of blood biomarkers, and difficulties in obtaining consent from stroke patients) but also for reasons that related to laboratory measurement of these biomarkers (pre-analytical and analytical issues as well as interpretation of laboratory measurements). Until today, many biomarkers have been identified, however none so far have shown sufficient sensitivity and specificity in order to be used in the clinical setting. In this review, we will focus on ischemic stroke and we aim to highlight these problems and also investigate if these are due to stroke complexity or due to our limited knowledge of pre-analytical requirements for many of these molecules and the questionable quality of the assays used.